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Abstract 
Preclinical studies indicate that brain-derived neurotrophic factor (BDNF) is involved in 
neuroplastic changes underlying enduring cocaine-seeking following withdrawal. 
However, little is known about temporal changes in serum BDNF levels or the 
involvement of BDNF in craving and abstinence in early-abstinent cocaine-dependent 
patients. Twenty-three cocaine-dependent individuals (aged 33.65 ± 6.85 years) 
completed a two-week detoxification program at an inpatient facility. Two serum 
samples were collected for each patient at baseline and at the end of the protocol.  
Serum samples were also collected for 46 healthy controls (aged 35.52 ± 9.37 years). 
Demographic, consumption and clinical data were recorded for all patients. 
Significantly lower serum BDNF levels (p<.0001) were observed for cocaine-dependent 
patients at baseline compared to healthy controls. Serum BDNF levels increased 
significantly across 12 days of early abstinence (p = .030). Baseline BDNF levels 
correlated with craving (p = .034). Post-detoxification BDNF levels correlated with 
craving (p = .018), loss of control (p < .000), abstinence measures (p = 0.031), 
depression (p = 0.036), and anxiety (p = 0.036). Post-detoxification BDNF levels also 
had predictive value for the loss of control measure of craving. Chronic cocaine use is 
associated with decreased serum BDNF. A progressive increase in serum BDNF levels 
during early abstinence correlates with cocaine craving and abstinence symptoms and 
may reflect increasing BDNF levels in different brain regions. These findings suggest 
that serum BDNF may be a biomarker for cocaine addiction. 
 
Key words: Abstinence; Addiction; Cocaine; Craving; Brain-Derived Neurotrophic 
Factor; BDNF 
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Introduction 
 Despite cocaine abuse is a significant public health problem, an effective 
pharmacotherapeutic treatment is still lacking (Castells et al., 2010). Identification of 
candidate biomarkers could assist in the development of effective pharmacological 
agents.  
 There is now considerable evidence that neurotrophins such as brain-derived 
neurotrophic factor (BDNF) and its intracellular signaling pathways are involved in 
psychostimulant abuse and dependence (see Corominas et al., 2007 for a review). A 
single infusion of cocaine increases BDNF expression in the nucleus accumbens (NAc) 
(Filip et al., 2006) and prefrontal cortex (PFC) (Le Foll et al., 2005). Cocaine self-
administration increases BDNF expression in the rat PFC, thereby modifying the 
reinforcing effects of cocaine (Sadri-Vakili et al., 2010). In rodents treated repeatedly 
with cocaine, brain BDNF expression increases progressively after withdrawal (Grimm 
et al., 2003; Pu et al., 2006).These studies also suggest that the progressive increase in 
BDNF expression in different brain areas after withdrawal is involved in incubation of 
cocaine craving (Grimm et al., 2003) and depressive behavioral symptoms (Filip et al., 
2006). Additionally, overexpression of BDNF in the mesolimbic system enhances 
locomotor sensitization and the rewarding effects of cocaine (Bahi et al., 2008). Finally, 
heterozygous BDNF knockout mice (BDNF+/-) are less sensitive to the psychomotor 
stimulant and the rewarding effects of cocaine (Hall et al., 2003). 
Since BDNF crosses the blood-brain barrier in both directions (Pan et al., 1998) 
and can be measured in serum and plasma (Fujimura et al., 2002), serum BDNF levels 
may reflect brain BDNF levels (Klein et al., 2011). The first study assessing BDNF in 
cocaine addicts found no difference in BDNF serum levels in 15 cocaine addicts and a 
group of healthy controls (Angelucci et al., 2007). However, a recent cross-sectional 
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study of 22 cocaine-dependent individuals reported a significant correlation between 
serum BDNF and number of abstinence days (Hilburn et al., 2011) and recently, BDNF 
was reported to be increased after 3 weeks of withdrawal (D’Sa et al., 2011). 
In abstinent cocaine-dependent patients, an intense desire for the drug (craving) 
and symptoms of physical and mental distress are strong predictors of relapse (Garavan 
et al., 2000). However, no controlled studies have linked these symptoms with blood 
BDNF levels. In the present study, we explored whether serum BDNF levels are a 




Patients met the diagnostic of cocaine addiction, according to the DSM-IV 
(American Psychiatric Association, 2000) criteria and were drawn from a cohort 
involved in an independent clinical study (ClinicalTrials.gov Identifier: NCT00495092). 
Exclusion criteria included: 1) Lifetime history of substance use disorder except 
nicotine; 2) lifetime history of psychotic, bipolar, or substance abuse disorders; 3) 
current history of mood, psychotic or anxiety disorder; 4) organic illness; 5) being 
currently under psychotropic medication at least one month before joining the protocol; 
6) seropositive for HIV; 7) psychotic symptoms during abstinence from or consumption 
of cocaine; 8) patients on chronic drug therapy with corticosteroids, thyroid hormones, 
allergy and/or analgesics. Sixty-two cocaine-dependent patients were assessed for 
eligibility; of these, 23 met the diagnostic criteria for inclusion (Figure 1). A gender- 
and age-matched sample of 46 healthy controls was also included. All participants were 
Caucasian and unrelated to one another. 
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This study was approved by the Clinical Research Ethics Committee of the University 
Hospital Vall d’Hebron. Written informed consent was obtained from all participants.  























Patients included in the clinical 
trial assessed for eligibility 
(n=61) 
Excluded (n=19) 
¨   Not meeting inclusion criteria (n=3) 
¨   Never came to treatment (n=7) 
¨   Drop out from the trial (n=4) 
¨   Other reasons (n=5 ) 
Excluded in this study because of 
psychotic symptoms (n= 17) 
 
Analysis of first blood extraction (n=40) 
Lost to follow-up for BDNF analysis (n=4) 
¨   Drop out from the trial (n=3) 
¨   Other reasons (n= 1) 
 
Analysis of second blood extraction (n=19) 
No psychotic symptoms (n=23) 
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Inpatient Procedure 
Two clinicians independently examined the patients and determined whether 
they met the criteria for inclusion. Patients were admitted to the inpatient unit of the 
Department of Psychiatry, Vall d’Hebron University Hospital, for 12 days. The 
inpatient unit is a locked treatment facility in which patients have no access to alcohol 
or drugs and limited visitation. Drug testing was conducted twice to ensure abstinence. 
Smoking was permitted during a maximum of six breaks per day previously established 
by the medical team. 
As part of the independent clinical study, patients received caffeine (starting 
dose of 300 mg/d; dose increased by 300 mg/d; maximum dose was 15 mg/kg/d up to 
1200 mg/d) and Biperiden (4 to 8 mg/day) or matched placebo. Caffeine was 
administered to improve patients’ comfort and Biperiden was administered to avoid 
tolerance to caffeine (ClinicalTrials.gov Identifier: NCT00495092). No additional 
psychotropic medication was administered except Lorazepam (up to 5 mg/d) for the 
treatment of insomnia. 
Clinical Assessment 
Psychiatric diagnoses and cocaine dependence were evaluated with the 
Structured Clinical Interview for DSM-IV-TR (SCID) I and II. The Visual Analogic 
Scale (VAS) Craving for cocaine, the State Trait Anxiety Inventory, the Beck 
Depression Inventory, the Cocaine Craving Questionnaire (CCQ) and the Cocaine 
Selective Severity Assessment, were administered. 
The CCQ included five dimensions of cocaine craving: a) desire, b) anticipation 
of positive reinforcement, c) anticipation of negative reinforcement, d) intention and 
planning to consume, and e) perceived lack of control over use. 
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Blood sample collection AND BDNF measurements 
Blood samples were collected twice, the first, immediately after arriving at the 
impatient facility and the second one, after twelve detoxification days. All patients had 
consumed cocaine the day before admission. 8 ml of blood was collected in 
anticoagulant-free tubes, kept at 4ºC for two hours, centrifuged at 3500 × g for 10 min 
at 4ºC and serum stored at -80ºC until performance of the BDNF assay. All samples 
were collected at fasting state and between 10 and 12 h to avoid circadian variations.  
Levels of human BDNF in serum samples were measured using Aushon 
SearchLight Multiplex Array (Aushon BioSystems, Billerica, MA) a sandwich enzyme-
linked immunosorbent system. Each sample was analyzed twice and the mean of the 
two BDNF measurements was used. All mean intra-assay coefficients of variation were 
less than 20%.   
Statistical analyses 
Chi squared (for demographic categorical variables) and U Mann Whitney tests 
(for BDNF serum levels) were used to analyze differences between patients and controls 
and Wilcoxon signed-rank test for longitudinal changes in treated patients. Boxplots 
were additionally used to describe quartile (Q1), median (Q2) and upper quartile (Q3) of 
BDNF serum levels in both samples (pre and post in the case of patients), as they didn’t 
follow a normal distribution. Spearman’s Rho was used to correlate BDNF with age, 
consumption variables and baseline clinical (abstinence, craving, depression, anxiety) 
measures. Kruskall wally’s test was used to analyze the differences between the three 
treatment groups.  A stepwise linear regression was used to assess the best clinical 
baseline correlates in BDNF serum change among the clinical sample. Statistical 
hypotheses were two-tailed and the risk alpha assumed was 5% in all analyses. All 
analyses were carried out using PASW Statistics software package, version 18. 
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Results 
Demographic characteristics and evaluation of clinical symptoms 
The clinical group consisted of 23 cocaine addicts (21 men and 2 women) and 
46 healthy matched controls (41 men and 5 women). Comparison of basic demographic 
data (gender and age) of patients and controls can be seen in table 1. No statistically 
significant differences were found for both variables between groups. Clinical and 
sociodemographic data of the clinical sample can be found in table 2. 
Table 1. Sociodemographic features by patient and control groups. 
 PATIENTS (n=23)  CONTROLS (n=46)  Significance  
Gender (% female) N % N % χ² p 
 2 8.7 5 10.9 0.79 .778 
Age M SD M SD t p 
 33.65  6.85 35.52 9.37 -.849 .399 
  
Table 2. Clinical information of patients. Includes consumption data, craving, 
depression and anxiety measures at detoxification treatment baseline. VAS: Visual 
Analogic Scale Craving for cocaine; CCQ: Cocaine Craving Questionnaire; CSSA: 
Cocaine Selective Severity Assessment; BDI: Beck Depression Inventory; STAI: State 
Trait Anxiety Inventory. 
 
Consumption variables Mean SD 
Age of onset 23.95 13.65 
Days of consumption in the last month 20.77 7.55 
Consumption episodes in the last month 3.53 2.48 
Maximum quantity in 24 hours in the last month (g) 3.31 4.13 












Baseline1 addiction measures   
VAS (1-10) 3.27 3.33 
CCQ   
 Desire 22.00 10.61 
 Intention 23.63 9.23 
 Anticipation 21.19 9.77 
 Relief 21.44 7.79 
 Loss of control 42.88 17.03 
CSSA (18 symptoms) 13.21 9.56 
Baseline1 clinical measures   
BDI, (cut-off for moderate depression=7) 12.61 9.33 
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STAI, trait (Q3=28) 27.88 9.39 
STAI, state (Q3=25) 24.94 10.50 
  
 
Serum BDNF levels in controls and patients during early cocaine abstinence 
Fourteen patients received caffeine (three of them also with biperiden) and 9 
received placebo. No statistical significant differences were detected at baseline (z=-
.189, p=.877), post-detoxification (z=-1.352, p=.196) or increase (z=-1.690, p=.100) of 
BDNF serum levels between patients with or without caffeine treatment (for more 
information please see ClinicalTrials.gov Identifier: NCT00495092). Hence, all 
treatment groups were analyzed together. 
Table 3 presents the BDNF serum levels in controls, patients at baseline, and 
patients after 12 days of abstinence. BDNF levels were significantly lower in patients at 
baseline than in controls (z = -3.488; p < .0001). BDNF levels increased significantly in 
patients across 12 days of abstinence (z = -2.173; p = .030). Analyses of normality 
showed that in patients, skewness and kurtosis was near 0 both at intake and after 12 
days of abstinence, whereas in controls skewness was 1.6 and kurtosis was 3.6, 
indicating a leptokurtic distribution. Figure 2 depicts Q1, Q2, and Q3 in controls, 
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Table 3.  Means (M) and standard deviations (SD) of Brain Derived Neurotrophic 
Factor (BDNF) among healthy controls and cocaine addicted patients. Significant 
differences were found between patients and controls at baseline and longitudinally 
among patients between baseline and 12 days of abstinence (post-detoxification). 
 
 PATIENTS  CONTROLS  Significance  
 M SD M SD z p 
BDNF baseline 51.676 17.505 76.044 32.661 -3.488 <.0001 
BDNF post 
detoxification 
60.643 22.607 76.044 32.661 -1.630 .103 
Significance z=-2.173 p=.030     
 
 
Figure 2. Boxplot of BDNF serum levels. Serum brain-derived neurotrophic factor 
(BDNF) levels (ng/mL median) obtained from the control group (left; n=46), for the 
patients group at baseline (middle, patients pre, n=23) and after 12 days of early detox- 
ification treatment (right, patients post, n=23). Statistical sig- nificant differences in 
BDNF serum levels were found (1) at baseline between controls and patients and (2) 






 Página 11 de 21 
Correlations between BDNF levels and demographic factors and clinical symptoms 
No correlation was found between BDNF levels and age among patients or 
controls. We were unable to assess correlations of BDNF levels with gender due to the 
small number of females in our sample. No differences were found between 
pharmacological treatment groups hence, we pooled the patient data for these analyses. 
Of the clinical symptom measures, only craving VAS correlated significantly 
with baseline BDNF serum levels in patients. By contrast, post-detoxification BDNF 
levels correlated with craving VAS, CCQ loss of control, CSSA, BDI, and STAI trait. 
The increase in BDNF levels from intake to post-detoxification correlated with craving 
VAS, CCQ loss of control, CSSA, and BDI (Table 4). 
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Table 4. Non parametric correlations and significance levels of serum Brain Derived Neurotrophic Factor (BDNF) with clinical and severity 
variables. Includes BDNF measures at detoxification treatment baseline (BDNF baseline), measures of BDNF after 12 days of treatment (BDNF 
post detoxification) and BDNF differences between baseline and post detoxification (BDNF difference). VAS: Visual Analogic Scale Craving 
for cocaine; CCQ: Cocaine Craving Questionnaire; CSSA: Cocaine Selective Severity Assessment; BDI: Beck Depression Inventory; STAI: 
State Trait Anxiety Inventory. 
 
 BDNF baseine  BDNF post 
detoxification 
 BDNF difference  
 Correlation Significance Correlation Significance Correlation Significance 
Consumption variables       
Age of onset -.135 .560 .022 .933 .124 .635 
Consumption in the last month .216 .422 .364 .201 .335 .241 
Baseline addiction measures       
VAS .453 .034 .550 .018 .558 .016 
CCQ       
 Desire .086 .760 .216 .478 .427 .146 
 Intention -.125 .644 .215 .481 .407 .167 
 Anticipation .043 .875 .086 .781 .014 .964 
 Relief .010 .970 -.148 .629 .044 .887 
 Loss of control .207 .442 .859 .000 .723 .005 
CSSA .161 .583 .647 .031 .697 .017 
Baseline clinical measures       
BDI .030 .906 .543 .036 .570 .027 
STAI, trait .110 .684 .583 .036 .457 .117 
STAI, state .122 .652 .327 .275 .382 .197 
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We carried out a stepwise regression to identify the baseline measure that was 
most predictive of the change in BDNF levels in patients. The loss of control subscale 
of the CCQ was the only variable that remained in the model (β = .840; p < .005). The 
model was statistically significant (F = 16.81; p < .005) and the percentage of explained 
variance was 71% (R-squared = .706). Figure 3 shows a scatterplot comparing the 
change in BDNF levels to baseline loss of control CCQ scores, along with a regression 
line. 
Figure 3. Scatter plot and regression line of BDNF serum level change 
(difference between baseline and post-early detoxifica- tion) and baseline loss of control 
Cocaine Craving Questionnaire (CCQ) scores. Statistically significant correlations were 
observed between change in BDNF levels and baseline CCQ loss of control. 
 
 
 Página 14 de 21 
Discussion 
Due to the small sample size, the results of this study have to be considered as 
preliminary and future studies involving larger samples will be needed. In interpreting 
these results, it is also necessary to take into account that about half of the patients 
received oral caffeine during detoxification. Although BDNF is increased after caffeine 
administration to zebrafish whose embryos were previously treated with caffeine 
(Capiotti et al., 2011) or in caffeine-treated sleep-deprived rats (Alhaider et al., 2011), 
we did not find differences in BDNF serum levels between caffeine- and placebo-
treated abstinent cocaine addicts. This may be due to the predominance of cocaine 
withdrawal over the stimulant effects of caffeine, an antagonist of adenosine receptors, 
during the first two abstinence weeks. Hence, for further comparisons in this study, data 
from all treatment groups were pooled and analyzed together. 
Our results show a decrease of serum BDNF levels in cocaine dependent 
individuals, suggesting neurotoxic effects induced by chronic cocaine consumption. We 
also observed a significant increase in BDNF serum levels in cocaine-dependent 
individuals during early abstinence with the magnitude of the increase being predictive 
of craving. The low levels of serum BDNF in cocaine-dependent patients compared to 
healthy controls was somewhat unexpected, as preclinical studies in rodents report an 
increase in BDNF protein expression in different brain regions following acute cocaine 
(Le Foll et al., 2005; Liu et al., 2006). There are several possible explanations for this 
apparent inconsistency. First, chronic cocaine administration may have different effects 
than acute cocaine administration. Preclinical studies report no change in BDNF protein 
levels in the first days after withdrawal from chronic cocaine (Grimm et al., 2003; Pu et 
al., 2006) and clinical studies with human addicts show no differences in BDNF serum 
levels between addicts and healthy controls (Angelucci et al., 2007).  
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 Second, the effects of chronic cocaine consumption and withdrawal in humans 
differ in several respects from those seen in animal models. For example, stress 
vulnerability, anxiety, and depression are associated with cocaine abuse in humans 
(Herrero et al., 2008) and this may explain low BDNF levels reported in this study. 
Indeed, in our sample of cocaine-dependent patients, baseline anxiety and depression 
were moderately high (Table 2). Chronic stress prevents cocaine-induced BDNF up-
regulation in the PFC (Fumagalli et al., 2009), and low serum BDNF has been 
consistently reported as a biomarker for depressive-like states (Schmidt and Duman, 
2010). Additionally, cocaine dependence is associated with dysregulation of the 
hypothalamic-pituitary-adrenal axis and increased cortisol (Fox et al., 2009) which  in 
turn is associated with a decrease in BDNF expression (Fanous et al., 2010). According 
to the role of BDNF in the regulation of neuronal connectivity, synaptic plasticity and 
survival of dopamine neurons (Thoenen, 1995; Fritsch et al., 2011), low BDNF serum 
levels in cocaine-dependent patients may induce neuronal toxicity and thereby 
compromise synaptic plasticity in mesolimbic regions. 
Our findings show a significant increase in serum BDNF levels over the first 12 
days of abstinence (table 3) that appears to be independent of the caffeine treatment. 
Serum BDNF increased in patients being in an inpatient facility with locked doors and 
small and controlled environmental space that may have prevented a greater increase of 
BDNF during withdrawal treatment. This reported increase is consistent with preclinical 
models in which BDNF increases progressively in the brain (Pu et al., 2006; Sadri-
Vakili et al., 2010) up to 90 days of abstinence (Grimm et al., 2003). Our results are 
also in accordance with D’sa et al. (2011) who reported higher BDNF serum levels in a 
sample of cocaine-dependents after three abstinence weeks as compared to healthy 
controls. These changes in serum BDNF during early cocaine abstinence may be due to 
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compensatory mechanisms to the neurotoxic effects of chronic cocaine (Sadri-Vakili et 
al., 2010). 
One of the main findings of our study is the significant positive relationship 
between the increase in serum BDNF levels over early abstinence and cocaine craving. 
This finding is consistent with previous research. In rodent cocaine self-administration 
models, there is a positive relationship between the increase of BDNF in brain regions 
and cue-induced drug-seeking after cocaine withdrawal (Grimm et al., 2003). In addicts, 
serum BDNF correlates with the time of cocaine relapse (D’sa et al., 2011). We also 
found a positive relationship between symptoms of abstinence, anxiety, and depression 
and increasing serum BDNF levels during early abstinence. In neuroimaging, cue-
elicited cocaine craving in addicts is associated with activation of mesocorticolimbic 
areas (Garavan et al., 2000). Given the role of BDNF in the regulation of neuronal 
connectivity and synaptic plasticity (Thoenen, 1995;  Fritsch et al., 2011), our data 
suggest functional changes in mesolimbic neuronal networks during cocaine abstinence 
which may underlie abnormal brain activation and emotional and behavioral correlates 
of cocaine craving. Together these data suggest that serum BDNF levels may be a 
biomarker of neuroplastic changes that lead to loss of control over consumption and to 
relapse. 
In conclusion, chronic cocaine use is associated with decreased baseline serum 
BDNF levels and serum BDNF levels rise during early abstinence. The progressive 
increase in serum BDNF levels during early withdrawal may reflect rising BDNF levels 
in brain regions involved in cocaine craving. Furthermore, these changes in BDNF 
expression may affect synaptic plasticity in regions of the mesolimbic system that 
underlie craving and contribute to addiction. Taken together, these findings suggest that 
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serum BDNF levels may be a biomarker in cocaine addiction. Pharmacological agents 
that interact with BDNF may have clinical utility in the treatment of cocaine addiction. 
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